Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3243808,recoveries,"Statistical analyses indicate average recoveries of 98.1 +/- 18.0 and 104.4 +/- 15.6% from plasma and urine, respectively.",Gas chromatographic determination of guanadrel in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243808/),%,98.1,63149,DB00226,Guanadrel
,3243808,recoveries,"Statistical analyses indicate average recoveries of 98.1 +/- 18.0 and 104.4 +/- 15.6% from plasma and urine, respectively.",Gas chromatographic determination of guanadrel in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243808/),%,104.4,63150,DB00226,Guanadrel
,2715368,terminal elimination half-life,The terminal elimination half-life was significantly prolonged in subjects with a creatinine clearance (ClCr) less than 30 mL/min/1.73 m2 (19.2 +/- 16.8 h) compared to 3.7 +/- 1.9 h in subjects with a ClCr greater than 80 mL/min/1.73 m2.,Disposition of guanadrel in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715368/),h,19.2,201662,DB00226,Guanadrel
,2715368,terminal elimination half-life,The terminal elimination half-life was significantly prolonged in subjects with a creatinine clearance (ClCr) less than 30 mL/min/1.73 m2 (19.2 +/- 16.8 h) compared to 3.7 +/- 1.9 h in subjects with a ClCr greater than 80 mL/min/1.73 m2.,Disposition of guanadrel in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715368/),h,3.7,201663,DB00226,Guanadrel
,2715368,Apparent volume of distribution,Apparent volume of distribution averaged 11.5 +/- 8.9 L/kg and did not differ in patients with decreased renal function compared to those with normal renal function.,Disposition of guanadrel in subjects with normal and impaired renal function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715368/),[l] / [kg],11.5,201664,DB00226,Guanadrel
,3896742,half-life,"Guanadrel has a rapid onset of action and a half-life of about 10 hours, thus dose titration can be achieved more rapidly than with guanethidine, and twice daily administration is appropriate.",Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896742/),h,10,223353,DB00226,Guanadrel
